Cyclophosphamide ameliorates membranous nephropathy by upregulating miR-223 expression, promoting M2 macrophage

Chunying Yao1, Qiubo Ma1, Ying Shi1

  • 1Department of Nephrology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.

Abstract

Insights

Cyclophosphamide (CTX) treatment upregulates miR-223, promoting M2 macrophage polarization and reducing inflammation in membranous nephropathy (MN). This study reveals miR-223's role in CTX's therapeutic effects on MN.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Membranous nephropathy (MN) is a primary cause of adult nephrotic syndrome.
  • Pathological hallmarks include immune complex deposition, basement membrane thickening, and foot process fusion.

Purpose of the Study:

  • Investigate miR-223's role in cyclophosphamide (CTX)'s immunosuppressive and anti-inflammatory actions in MN.
  • Elucidate the mechanism of CTX in modulating immune responses relevant to MN.

Main Methods:

  • Utilized miR-223 mimetics/inhibitors to modulate miR-223 levels.
  • Employed lipopolysaccharide (LPS)-induced inflammatory cell models and a cationic bovine serum albumin (c-BSA)-induced mouse MN model.
  • Assessed the effects of CTX on inflammatory responses, cell polarization, and renal injury.

Main Results:

  • miR-223 levels were lower in LPS-induced inflammatory cells.
  • CTX and miR-223 mimetics reduced inflammatory factors.
  • CTX treatment increased M2 macrophage markers (Arg1, TGF-β1, IL-4, IL-13) and alleviated renal injury in the MN model.

Conclusions:

  • Cyclophosphamide (CTX) upregulates miR-223 expression.
  • CTX promotes M2 macrophage polarization, mitigating inflammation and renal injury in membranous nephropathy.

Related Concept Videos